1. AB0371 Is Switching from IV To SC Abatacept Therapy Sustainable in The Real World? 1-Year Analysis of The Prospective, International Action Study. (15th July 2016) Authors: Alten, R.; Nüßlein, H.; Galeazzi, M.; Lorenz, H.M.; Mariette, X.; Cantagrel, A.; Chartier, M.; Elbez, Y.; Rauch, C.; Le Bars, M. Journal: Annals of the rheumatic diseases Issue: Volume 75(2016)Supplement 2 Page Start: 1030 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. AB0453 Do Changes in Clinical Practice Over Time in Europe and Canada Have an Impact on Baseline Characteristics of Patients Initiating Intravenous Abatacept in the Action Study?. (9th June 2015) Authors: Nüβlein, H.; Alten, R.; Galeazzi, M.; Lorenz, H.-M.; Cantagrel, A.; Chartier, M.; Poncet, C.; Rauch, C.; Le Bars, M. Journal: Annals of the rheumatic diseases Issue: Volume 74(2015)Supplement 2 Page Start: 1047 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. AB0461 Experience with subcutaneous abatacept in routine clinical practice: 6-month interim analysis of a 2-year, prospective, non-interventional, multicentre study in patients with ra. (12th June 2018) Authors: Alten, R.; Mariette, X.; Buch, M.; Caporali, R.; Flipo, R.-M.; Forster, A.; Griffiths, H.; Nurmohamed, M.; Patel, Y.; Peichl, P.; Sanmarti, R.; Chauvet, C.; Heitzman, J.; Rauch, C.; Connolly, S.E. Journal: Annals of the rheumatic diseases Issue: Volume 77(2018)Supplement 2 Page Start: 1392 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
4. AB0477 Retention Rates and Clinical Outcomes in Cohorts of Patients (Biologic Naïve or Failed Prior Biologics) Treated with Intravenous Abatacept in a Real-World Setting: 6-Month Results from the Action Study. (9th June 2015) Authors: Alten, R.; Nüßlein, H.; Galeazzi, M.; Lorenz, H.-M.; Mariette, X.; Cantagrel, A.; Chartier, M.; Poncet, C.; Rauch, C.; Le Bars, M. Journal: Annals of the rheumatic diseases Issue: Volume 74(2015)Supplement 2 Page Start: 1056 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
5. AB0531 Real-world efficacy and safety of abatacept treatment for RA: 12-month interim analysis of the action study. (23rd January 2014) Authors: Nüßlein, H.; Alten, R.; Galeazzi, M.; Lorenz, H.M.; Boumpas, D.; Nurmohamed, M.T.; Bensen, W.G.; Burmester, G.R.; Peter, H.H.; Rainer, F.; Pavelka, K.; Chartier, M.; Poncet, C.; Rauch, C.; Le Bars, M. Journal: Annals of the rheumatic diseases Issue: Volume 71(2012)Supplement 3 Page Start: 668 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
6. AB0532 Effect of prior therapy on the efficacy and safety of abatacept: 6-month analysis of the action study. (23rd January 2014) Authors: Nüßlein, H.; Alten, R.; Galeazzi, M.; Lorenz, H.M.; Boumpas, D.; Nurmohamed, M.T.; Bensen, W.G.; Burmester, G.R.; Peter, H.H.; Rainer, F.; Pavelka, K.; Chartier, M.; Poncet, C.; Rauch, C.; Le Bars, M. Journal: Annals of the rheumatic diseases Issue: Volume 71(2012)Supplement 3 Page Start: 668 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
7. Characterisation of the TNFα Converting Enzyme (TACE/ADAM17) Deficient Mouse and Its Role in the Shedding of Cell Surface Proteins. (February 1999) Authors: Cerretti, P. P.; Rauch, C.; Kozlosky, K.; Nelson, N.; Reddy, P.; Peschon, J.; Slack, J.; Paxton, R.; Black, R. Journal: Biochemical Society transactions Issue: Volume 27:Number 1(1999) Page Start: A23 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
8. Development of human iPSC-derived renal cell models for toxicity testing. (16th September 2016) Authors: Wilmes, A.; Rauch, C.; Kern, G.; Feifel, L.; Gstraunthaler, G.; Jennings, P. Journal: Toxicology letters Issue: Volume 258(2016)Supplement Page Start: S143 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
9. FRI0235 Adherence to the recommended dosing regimen of abatacept: results from the international, real-world action study. (23rd January 2014) Authors: Nüßlein, H.; Alten, R.; Galeazzi, M.; Lorenz, H. M.; Boumpas, D.; Nurmohamed, M. T.; Bensen, W. G.; Burmester, G. R.; Peter, H.-H.; Rainer, F.; Pavelka, K.; Chartier, M.; Poncet, C.; Rauch, C.; Le Bars, M. Journal: Annals of the rheumatic diseases Issue: Volume 72:Supplement 3(2013) Page Start: A453 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
10. FRI0318 Two-Year Retention and Effectiveness of IV Abatacept in Real-Life Setting: Results from the Action Study. (10th June 2014) Authors: Nüβlein, H.; Alten, R.; Galeazzi, M.; Lorenz, H.-M.; Nurmohamed, M.; Bensen, W.; Burmester, G.-R.; Peter, H.-H.; Pavelka, K.; Chartier, M.; Poncet, C.; Rauch, C.; Le Bars, M. Journal: Annals of the rheumatic diseases Issue: Volume 73:Supplement 2(2014) Page Start: 500 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗